Table 1 Baseline characteristics of 194 stage I-III breast cancer participants treated with anthracyclines between 2007 and 2012. All participants with pair baseline and 12 weeks since start anthracycline LVEF evaluation by echocardiogram were divided into case (early LVEF decline > 10%) and control (no LVEF decline)
Parameters | All participants n = 194 | Participants with pair baseline and 12 weeks since start anthracycline LVEF evaluation by echocardiogram (n = 194) | ||
|---|---|---|---|---|
|  | LVEF decline ≥ 10% (n = 64) | No LVEF decline (n = 130) | p-value | |
Median age at breast cancer diagnosis, [range] (years) | 50 [26–72] | 51 [26–70] | 50 [30–72] | 0.76 |
BMI (kg/m2) at diagnosis | 24.6 ± 4.6 | 24.5 ± 4.3 | 24.6 ± 4.7 | 0.84 |
Hypertension, diabetes mellitus or dyslipidemia, n (%) | 74 (38.1) | 23 (35.9) | 43 (33.1) | 0.75 |
Baseline cardiovascular risk (HFA-ICOS), n (%) | ||||
 -Low risk  -Moderate risk  -High risk | 60 (30.9) 59 (30.4) 75 (38.7) | 17 (26.6) 21 (32.8) 26 (40.6) | 43 (33.1) 38 (29.2) 49 (37.7) | 0.64 |
History of smoking, n (%) | 5 (2.6) | 1 (1.6) | 2 (1.5) | 1.00 |
Menopause, n (%) | 65 (33.5) | 20 (31.3) | 45 (34.6) | 0.63 |
Cumulative doxorubicin-equivalent dose (mg/m2) | 223.2 ± 21.6 | 223.7 ± 18 | 222.9 ± 23.2 | 0.81 |
Baseline LVEF (%) by echocardiogram | 70.2 ± 7.1 | 74.3 ± 6.6 | 68.2 ± 6.5 | < 0.01* |
End-anthracycline LVEF by echocardiogram (%) | 66.6 ± 6.8 | 61.9 ± 6.1 | 68.9 ± 5.9 | < 0.01* |
Change of baseline and end-anthracycline LVEF (%) | -4.5 ± 11.9 | -16.5 ± 5.7 | 1.5 ± 9.4 | < 0.01* |
Subsequent anti-HER2 therapy, n (%) | 34 (17.5) | 16 (25.0) | 18 (13.8) | 0.07 |
Left chest wall radiation, n (%) | 68 (35.1) | 25 (39.1) | 43 (33.1) | 0.52 |
Documented symptomatic CTRCD, n (%) | 9 (4.6) | 1 (1.6) | 8 (6.2) | 1.00 |